63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03275740 (ClinicalTrials.gov) | July 17, 2017 | 6/7/2017 | A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA | Healthy;Primary Immune Thrombocytopenia;Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Drug: PF-06755347 intravenous healthy participant;Drug: Placebo intravenous healthy participant;Drug: PF-06755347 subcutaneous healthy participant;Drug: Placebo subcutaneous healthy participant;Drug: PF-06755347 subcutaneous ITP | Pfizer | NULL | Terminated | 18 Years | 55 Years | All | 58 | Phase 1 | United States;Belgium;New Zealand;Spain;United Kingdom |